CG Oncology
Manufacturing · Texas, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
3000 Pegasus Park Dr Ste 1640, Dallas, T...Phone Number
(949) 409-3700Website
www.cgoncology.comRevenue
$6.2 MillionStock Symbol
CGONIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About CG Oncology
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. At CG Oncology, we see a world where urologic cancer patients can benefit from their innovative immunotherapies to live with dignity and have an enhanced quality of life.Explore more
CG Oncology Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is CG Oncology your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if CG Oncology had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if CG Oncology is spiking on competitors!
CG Oncology, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on CG Oncology recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at CG Oncology
Product Launch: Get notified when CG Oncology launches new products
Check if CG Oncology has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once CG Oncology has new funding data
Recommended Actions
Find VP level buyers at CG Oncology
Find 2 more new buyers
Compare Similar Companies to CG Oncology
Compare insights from companies similar to CG Oncology, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
CG Oncology is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
CG Oncology is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about CG Oncology.
CG Oncology financials insights
Gather financial insights about CG Oncology, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Series A
$13.6M
2015
Series B
$10M
2019
Series C
$22M
2020
Series D
$47M
2022
Series E
$120M
2023
Other Financing Round
$105M
2024
Stock Offering
$380M
CG Oncology Tech Stack
A closer look at the technologies used by CG Oncology
See more technologies
Most Recent Scoops
Person-Based
Pharmaceuticals, Clinical Operations
Person-Based
Pharmaceuticals, Clinical Operations
Person-Based
Pharmaceuticals, Clinical Operations
Person-Based
Medical Research, Pharmaceuticals, Clinical Operations
Person-Based
Medical Research, Pharmaceuticals
CG Oncology News & Media
Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm
NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of CG Oncology, Inc. (NASDAQ: CGON) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing....CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates
DALLAS, Texas, Aug. 06, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the second quarter ended June 30, 2026, and provided business updates.CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology
Data reinforce durable responses, bladder preservation, low rate of disease progression, and favorable safety and tolerability in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer Data reinforce durable responses, bladder preservation, low rate of disease progression, and favorable safety and tolerability in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancerCG Oncology, Inc. (CGON) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
CG Oncology, Inc. (CGON) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 9, 2026 2:40 PM EDTCompany ParticipantsArthur Kuan - Chairman,...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding CG Oncology
Sign Up For FreeTo access detailed company insights
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. At CG Oncology, we see a world where urologic cancer patients can benefit from their innovative immunotherapies to live with dignity and have an enhance... Read More
